Niagen Bioscience, Inc. — Director's Dealing 2018

Dec 12, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2018-12-10

Reporting Person: Roberts Matthew A (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-12-10	Stock Option (right to buy)	$2.85	A	350000	Acquired	2028-12-10	Common Stock (350000)	Direct

Footnotes

F1: One-third of the shares subject to the option vest on December 10, 2019, and the remaining shares subject to the option vest in a series of 24 equal monthly installments thereafter on each such vesting date.